ClinicalTrials.gg

Program

frespaciguat

Also written as “Frespaciguat” and “[14C] MK-5475”.

Its studies are mostly in Hypertension, Pulmonary · Pulmonary Arterial Hypertension · COVID-19, led by Merck.

Furthest: phase 3, since Jan 27, 20216 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck61 open or runningphase 3since Jan 27, 2021Nov 13, 2018none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 13, 2018First study: phase 1 study in Pulmonary Arterial HypertensionFirst studyNCT03744637 · 25 enrolled · Moldova, Republic of
  2. Apr 29, 2020Phase 1 study in Hypertension, PulmonaryNCT04370873 · 22 enrolled · United States, Israel, Moldova, Republic of
  3. Jun 8, 2020Phase 1 study in COVID-19NCT04425733
  4. Jan 27, 2021Phase 3 study in Pulmonary Arterial HypertensionNCT04732221 · 168 enrolled · United States, Argentina, Australia and more
  5. Nov 3, 2022Phase 2 study in Hypertension, PulmonaryNCT05612035 · 129 enrolled · United States, Argentina, Australia and more
  6. Jan 10, 2025Phase 1 study in HealthyNCT06777602 · 8 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06777602Healthy · United States1CompletedSep 30, 20228
NCT05612035Hypertension, Pulmonary · United States, Argentina, Australia and more2Active, not recruitingApr 9, 2026129
NCT04732221Pulmonary Arterial Hypertension · United States, Argentina, Australia and more3CompletedJan 4, 2024168
NCT04425733COVID-191WithdrawnNov 10, 20200
NCT04370873Hypertension, Pulmonary · United States, Israel, Moldova, Republic of1CompletedJan 12, 202222
NCT03744637Pulmonary Arterial Hypertension · Moldova, Republic of1CompletedDec 11, 202025

How it is read

Names in the registry

  • “Frespaciguat”, 5 entries
  • “[14C] MK-5475”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
frespaciguat (Merck): development program | ClinicalTrials.gg